Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
11 juin 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
PathMaker Neurosystems Announces $2.16 Million Award from U.S. Department of Defense for ALS Clinical Trial
05 juin 2024 06h00 HE
|
PathMaker Neurosystems Inc.
PathMaker Neurosystems receives $2.16 million award from United States Department of Defense for an expanded ALS clinical trial of its MyoRegulator device
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
04 juin 2024 09h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
31 mai 2024 10h30 HE
|
AB Science
COMMUNIQUE DE PRESSE RESUME DE LA CONFERENCE VIRTUELLE DU 30 MAI 2024 FAISANT LE POINT SUR LA DEMANDE D'AUTORISATION CONDITIONNELLE DE MISE SUR LE MARCHE DU MASITINIB DANS LE TRAITEMENT...
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
31 mai 2024 10h30 HE
|
AB Science
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
30 mai 2024 16h51 HE
|
Biogen Inc.
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the...
Muscular Dystrophy Association’s Impact to End ALS Continues with Fourth Annual Lou Gehrig Day at Major League Baseball Games
21 mai 2024 09h07 HE
|
Muscular Dystrophy Association
New York, May 21, 2024 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) is gathering its extended community at Major League Baseball (MLB) parks across the United States, uniting ALS...
Muscular Dystrophy Association Celebrates Historic Advancements in Accessible Air Travel as Congress Passes FAA Reauthorization
15 mai 2024 14h57 HE
|
Muscular Dystrophy Association
Washington, D.C., May 15, 2024 (GLOBE NEWSWIRE) -- Today, the Muscular Dystrophy Association (MDA) celebrates a landmark achievement in accessible air travel as Congress grants final passage to the...
United for a Cure: ALS Super Fund, backed by Canadian NHL teams, hits $1 Million With Charitable Impact’s Cause Fund
14 mai 2024 16h28 HE
|
Charitable Impact
VANCOUVER, BC, May 14, 2024 (GLOBE NEWSWIRE) -- With tremendous support from Canada's seven National Hockey League (NHL) teams, individuals and several communities, the ALS Super Fund has achieved a...
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
07 mai 2024 12h05 HE
|
AB Science
PRESS RELEASE A NEW PUBLICATION IN THE MEDICAL JOURNAL MUSCLE & NERVE VALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN OF CLINICAL STUDIES AND THE TREATMENT CHOICE...